Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment

American Journal of Respiratory and Critical Care Medicine

Volumn 179, Issue 10, 2009, Pages 950-954

  Grigoriu, Bogdan D ^a,b   Chahine, Bachar ^c   Vachani, Anil ^d   Gey, Thomas ^c   Conti, Massimo ^c   Sterman, Daniel H ^d   Marchandise, Genevieve ^a   Porte, Henri ^c   Albelda, Steven M ^d   Scherpereel, Arnaud ^a,c  

^a INSTITUT PASTEUR DE LILLE   (France)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Marker; Neoplasm; Pleura; Prognosis

Indexed keywords

ADENOVIRUS VECTOR; BETA INTERFERON; CARBOPLATIN; CISPLATIN; GEMCITABINE; MESOTHELIN; PEMETREXED;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GENE TRANSFER; HUMAN; HUMAN TISSUE; INFUSION; KINETICS; MALE; MONITORING; OUTCOME ASSESSMENT; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; TREATMENT RESPONSE;

AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; FEMALE; GENE THERAPY; HUMANS; INTERFERON-BETA; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 65649133121     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200807-1125OC     Document Type: Article

References (29)

1. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp MM Jr, Swanson SJ, Bueno R, Lukanich JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63.
2. Neragi-Miandoab S. Multimodality approach in management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2006;29:14-19. (Pubitemid 43000349)
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644.
4. Armato SG III, Oxnard GR, MacMahon H, Vogelzang NJ, Kindler HL, Kocherginsky M, Starkey A. Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. Med Phys 2004;31:1105-1115. (Pubitemid 38656781)
5. Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, Nowak AK, Phillips M, Price R, Patrikeos AP, Musk AW, Millward MJ. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 2007;48:1449-1458. (Pubitemid 47397395)
6. Flores RM. The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer 2005;49:S27-S32. (Pubitemid 40798841)
7. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-1616. (Pubitemid 37443528)
8. Scherpereel A, Grigoriu BD, Conti M, Gey T, Gregoire M, Copin M-C, Devos P, Chahine B, Porte H, Lassalle P. Soluble mesothelin-related protein in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;173:1155-1160. (Pubitemid 43726897)
9. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Gregoire M, Porte H, Copin MC, Lassalle P. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007;13:2928-2935. (Pubitemid 46850705)
10. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C, Wali A. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005;353:1564-1573. (Pubitemid 41434635)
11. Ordonez NG. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol 2007;38:1-16.
12. Grigoriu B, Chahine B, Conti M, Kedziora L, Gey T, Copin MC, Lassalle P, Marchandise G, Porte H, Scherpereel A. Kinetics of serum soluble mesothelin related peptides and osteopontin in patients with malignant pleural mesothelioma under treatment [abstract]. Am J Respir Crit Care Med 2006;173:A864.
13. Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A, Kapoor V, Sun J, Hodinka R, Brown JL, et al. A phase I clinical trial of single-dose intrapleural IFN-{beta} gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 2007;13:4456-4466.
14. Byrne M, Nowak A. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004;15:257-260. (Pubitemid 38262625)
15. Creaney J, Christansen H, Lake R, Musk AB, de Klerk N, Robinson BW. Soluble mesothelin related protein in mesothelioma. J Thorac Oncol 2006;1:172-174. (Pubitemid 47164007)
16. Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, Neri M, Ceppi M, Paganuzzi M, Ivaldi GP, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007;13:5076-5081.
17. Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008;5:136-147.
18. Scherpereel A. Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma. Respir Med 2007;101:1265-1276. (Pubitemid 46671140)
19. Herndon JE II, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998;113:723-731.
20. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998;16:145-152. (Pubitemid 28041592)
21. Bottomley A, Coens C, Efficace F, Gaafar R, Manegold C, Burgers S, Vincent M, Legrand C, van Meerbeeck JP. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol 2007;25:5770-5776.
22. Legrand C, Gafaar R, Manegold C, van Klaveren R, Vincent M, Passioukov A, Giaccone G, van Meerbeeck J. Prognostic factor analysis of EORTC 08983: a randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM). Lung Cancer 2005;49:S224.
23. Thylen A, Hjerpe A, Martensson G. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer 2001;92:1224-1230.
24. Armato Iii SG, Entwisle J, Truong MT, Nowak AK, Ceresoli GL, Zhao B, Misri R, Kindler HL. Current state and future directions of pleural mesothelioma imaging. Lung Cancer 2008;59:411-420.
25. Greillier L, Cavailles A, Fraticelli A, Scherpereel A, Barlesi F, Tassi G, Thomas P, Astoul P. Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma. Cancer 2007;110:2248-2252. (Pubitemid 350100747)
26. Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003;16:192-197. (Pubitemid 36337423)
27. Sapede C, Gauvrit A, Barbieux I, Padieu M, Cellerin L, Sagan C, Scherpereel A, Dabouis G, Gregoire M. Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells. Cancer Sci 2007;99:590-594.
28. Ho M, Onda M, Wang QC, Hassan R, Pastan I, Lively MO. Mesothelin is shed from tumor cells. Cancer Epidemiol Biomarkers Prev 2006;15:1751. (Pubitemid 44497117)
29. Hellstrom I, Raycraft J, Kanan S, Sardesai NY, Verch T, Yang Y, Hellstrom KE. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 2006;15:1014-1020. (Pubitemid 43823532)